SHR 4849
Alternative Names: SHR-4849Latest Information Update: 31 Dec 2024
Price :
$50 *
At a glance
- Originator Suzhou Suncadia Biopharmaceuticals
- Class Antibodies; Antineoplastics; Drug conjugates; Immunoconjugates; Immunotherapies
- Mechanism of Action DNA topoisomerase I modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 29 Dec 2024 IDEAYA Biosciences plans to file an IND application with the US FDA for Solid tumours in the first half of 2025
- 29 Dec 2024 Interim adverse events and efficacy data from a phase-I trial in Solid tumours released by Suzhou Suncadia Biopharmaceuticals ,
- 26 Jun 2024 Phase-I clinical trials in Solid tumours (Late-stage disease) in China (Parenteral), (NCT06443489)